Fusion Antibodies upbeat on 'mixed but improving' performance
5th May 2026 12:07
(Sharecast News) - Fusion Antibodies said on Tuesday that full-year revenue rose and margins had improved sharply, as the pre-clinical antibody specialist made progress with platform development, grant-funded programmes and larger pharmaceutical customers.
Read moreFusion Antibodies enters deal to transfer IP to client
30th Mar 2026 11:07
(Sharecast News) - Fusion Antibodies said on Monday that it has entered into an agreement to transfer ownership of certain background intellectual property to an existing client, generating a one-off payment and supporting continued collaboration on antibody development.
Read moreFusion Antibodies posts narrower half-year loss
24th Nov 2025 12:54
(Sharecast News) - Fusion Antibodies reported a narrower first-half loss on Monday, as increased investment in its OptiMAL antibody discovery platform and a series of new contract wins helped improve performance despite lower year-on-year revenue.
Read moreFusion Antibodies expecting stronger second-half performance
16th Oct 2025 15:42
(Sharecast News) - Fusion Antibodies said on Thursday that it expects a stronger performance in the second half of the year after reporting first-half revenues of £0.84m, as operational efficiency improved and market sentiment began to recover.
Read moreFusion Antibodies reports further validation of OptiMAL platform
17th Sep 2025 09:42
(Sharecast News) - Fusion Antibodies reported further validation of its OptiMAL discovery platform on Wednesday, saying its collaboration with the US National Cancer Institute had confirmed antibody binders to three cancer targets and that the NCI had asked to extend its use of the technology beyond the current agreement, which runs to November 2025.
Read moreFusion Antibodies selected for follow-on projects
27th Aug 2025 08:10
(Sharecast News) - Pre-clinical antibody discovery specialists Fusion Antibodies said on Wednesday that it has been selected for three follow-on projects to its existing stable Cell Line Development project.
Read moreFusion Antibodies validation project with US NIC progresses
31st Jan 2025 10:09
(Sharecast News) - Fusion Antibodies announced on Friday that its OptiMAL validation project with the US National Cancer Institute (NCI) was progressing as planned.
Read moreFusion Antibodies reports positive recent trading
8th Oct 2024 15:40
(Sharecast News) - Fusion Antibodies reported positive trading in an update on Tuesday, highlighting significant progress for the first half of its financial year.
Read moreFusion Antibodies strengthens financial position despite revenue decline
5th Sep 2024 13:53
(Sharecast News) - Preclinical antibody discovery and engineering specialist Fusion Antibodies said in its final results on Thursday that despite a challenging year with a decline in revenue, it had strengthened its financial position and expanded its pipeline of opportunities.
Read moreFusion Antibodies 'on track and on plan' following positive Q1 performance
4th Jul 2024 09:50
(Sharecast News) - Antibody discovery specialist Fusion Antibodies said on Thursday that it was both "on track and on plan" following "positive momentum" throughout Q1.
Read moreFusion Antibodies gets first order under new services agreement
27th Feb 2024 13:15
(Sharecast News) - Fusion Antibodies announced the receipt of its first purchase order under a master services agreement on Tuesday, which it agreed with a prominent diagnostics company on 14 February.
Read moreFusion Antibodies raises £1.38m as it seeks new customers
14th Feb 2024 12:52
(Sharecast News) - Pre-clinical antibody specialist Fusion Antibodies announced a conditional fundraising of £1.38m before expenses on Wednesday, to help it target mo re industry conferences and customers and generate further supporting data.
Read moreFusion Antibodies confirms £0.28m tax credit
1st Feb 2024 16:27
(Sharecast News) - Preclinical antibody discovery specialist Fusion Antibodies announced the successful receipt of a research and development tax credit from HMRC on Thursday.
Read moreFusion Antibodies revenue falls, losses widen in first half
4th Dec 2023 12:01
(Sharecast News) - Contract research organisation Fusion Antibodies reported first-half revenue of £0.54m on Monday, down from £1.9m a year earlier.
Read moreFusion Antibodies appoints interim finance chief
24th Aug 2023 14:45
(Sharecast News) - Preclinical antibody developer Fusion Antibodies announced the immediate appointment of Stephen Smyth as its interim chief financial officer on Thursday.
Read more